Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy.

Kurtti, Amanda

Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy. [electronic resource] - Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners Sep 2020 - 1301-1305 p. digital

Publication Type: Journal Article

1477-092X

10.1177/1078155219890403 doi


Aged
Anti-Bacterial Agents--therapeutic use
Antibiotic Prophylaxis--trends
Antineoplastic Agents--adverse effects
Body Mass Index
Cohort Studies
Febrile Neutropenia--chemically induced
Female
Hematologic Neoplasms--drug therapy
Humans
Levofloxacin--therapeutic use
Male
Middle Aged
Obesity--drug therapy
Retrospective Studies
Risk Factors